Major cancer study aims to standardize test results across china

NCT ID NCT07404202

Not yet recruiting Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This study aims to see if different labs and pathologists get the same results when testing cancer tissue for the HER2 protein. Researchers will look back at tissue samples from about 2,100 Chinese patients with lung, gynecologic, bile duct, or bladder cancer. The goal is to understand how consistent these important diagnostic tests are across different hospitals and testing methods.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PAN-TUMOR(NSCLC, GYN CANCERS, BTC AND UC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.